170 M. L. L. Chatrou et al., “Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists.” Blood Reviews 26, no. 4 (July 2012): 155–66.

171 R. C. Morris et al., “Relationship and interaction between sodium and potassium.” Journal of the American College of Nutrition 25, no. 3 Suppl (June 2006): 262S–70S.

172 N. J. Aburto et al., “Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses.” BMJ (Clinical Research Ed.) 346 (January 2013): f1378.

173 S. C. Larsson et al., “Dietary potassium intake and risk of stroke: a dose-response meta-analysis of prospective studies.” Stroke: A Journal of Cerebral Circulation 42, no. 10 (October 2011): 2746–50.

174 Richard D. Moore et al., The Salt Solution (Avery, 2001).

175 F. Forouzandeh et al., “Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis.” Journal of the American Heart Association 3, no. 6 (December 2014): e001202.

176 M. L. Wahlqvist et al., “Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson’s disease occurring with type 2 diabetes in a Taiwanese population cohort.” Parkinsonism and Related Disorders 18, no. 6 (July 2012): 753–58.

177 C. A. Bannister et al., “Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.” Diabetes, Obesity and Metabolism 16, no. 11 (November 2014): 1165–73.

178 R. I. Misbin, “The phantom of lactic acidosis due to metformin in patients with diabetes.” Diabetes Care 27, no. 7 (July 2004): 1791–93.

179 S. R. Salpeter et al., “Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.” Cochrane Database of Systematic Reviews 1 (January 2010): CD002967.